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Background: Cognitive behavioural therapy (CBT) is effective for the treatment of common 
mental health problems, but the number of sessions required to maximise improvement in 
routine care remains unclear.  
Aim: This study aimed to examine the dose-response effect in low (LiCBT) and high (HiCBT) 
intensity CBT delivered in stepped care services. 
Methods: A multi-service dataset included N = 102206 patients across N=16 services. The 
study included patients with case-level depression and/or anxiety symptoms who accessed 
LiCBT and/or HiCBT. Patients with post-treatment reliable and clinically significant 
improvement (RCSI) in standardised outcome measures (PHQ-9, GAD-7) were classified as 
treatment responders. Survival analyses assessed the number of sessions necessary to detect 
50%, 75% and 95% of treatment responders. The 50% and 95% percentiles were used to define 
the lower and upper boundaries of an adequate dose of therapy that could be used to inform 
the timing of treatment progress reviews. Analyses were then stratified by diagnosis, and cox 
regression was used to identify predictors of time-to-remission. 
Results: Most responders (95%) attained RCSI within 7 sessions of LiCBT and 14 sessions of 
HiCBT. Patients with social anxiety disorder, post-traumatic stress disorder, and obsessive-
compulsive disorder required HiCBT and lengthier treatments (6–16 sessions) to maximise 
improvement. 
Conclusions: Distinctive dose-response patterns are evident for LiCBT and HiCBT, which can 
be used to support treatment planning and routine outcome monitoring. 
 





The duration and associated costs of psychological treatment vary considerably in routine care. 
Taking an evidence-based approach, contemporary treatment guidelines for common mental 
health problems recommend a set number of sessions that are guided by efficacy trials 
(National Institute for Health and Care Excellence [NICE], 2011). However, such an approach 
is problematic because we cannot assume that trial participants are representative of patients 
encountered in routine care, or that all patients have a uniform response to the number of 
sessions that are set in clinical trials. Furthermore, clinical trial outcomes are usually 
aggregated at a group level (e.g., intervention cases vs. controls) and assessed at predefined 
endpoints (e.g., 6-months post-randomization), which precludes the investigation of 
differential response-times across different patients. For these reasons, it has been argued that 
practice-based studies with typically variable treatment durations, rather than controlled trials 
with arbitrary durations, are necessary to better understand the natural variability in response 
to therapy and to establish pragmatic recommendations for the optimal duration of treatment 
(Hansen, Lambert, & Forman, 2002; Robinson, Delgadillo, & Kellett, in press). 
Numerous practice-based studies since the 1980s have found associations between the 
duration of psychotherapy and symptomatic improvements (Hansen et al., 2002). This dose-
response effect is characterised by a curvilinear relationship, whereby most of the symptomatic 
improvement is observed during the earlier stages of treatment (Howard, Kopta, Krause, & 
Orlinsky, 1986). Researchers have sought to identify the point at which at least 50% of patients 
who attain clinically significant change are detected, and after which the probability of 
symptomatic improvement steeply declines (Hansen et al., 2002). Combining the 50% 
percentile and a higher percentile such as 75% or 95% would enable clinicians to determine 
adequate dose parameters, denoting the minimally acceptable number of sessions and a rational 
upper limit to decide if a patient is likely to respond to treatment with additional sessions 
4 
 
(Hansen et al., 2002; Howard et al., 1986; Robinson et al., in press). This approach recognises 
that patients’ trajectories of change are heterogeneous, since some respond quickly and others 
require lengthier interventions. However, a cause-effect relationship between treatment dose 
and clinical outcomes cannot be inferred from uncontrolled studies, since response rates are 
likely to be influenced by spontaneous remission. Nevertheless, the pragmatic utility of the 
dose-response model rests in the observation that most patients who attain remission of 
symptoms (due to therapy, regression to the mean, or spontaneous recovery) show signs of 
improvement by the upper boundary of the adequate dose. 
A systematic review of dose-response studies found that adequate dose 
recommendations varied according to clinical populations and methodological approach 
(Robinson et al., in press). For example, patients with psychosis required 8–30 sessions of high 
intensity cognitive behavioural therapy (CBT) (Falkenström, Josefsson, Berggren, & 
Holmqvist, 2016; Lincoln, Jung, Weisjahn, & Schlier, 2016), while patients with mild-to-
moderate anxiety and depression required only 4–6 sessions of low intensity CBT (Delgadillo 
et al., 2014; Delgadillo, Kellett, et al., 2016). Furthermore, studies using more or less 
conservative definitions of treatment response yield different conclusions (Anderson & 
Lambert, 2001; Asay, Lambert, Gregersen, & Goates, 2002). Overall, methodological reviews 
indicate that adequate dose parameters need to be calibrated in diagnostically homogenous 
groups, in large and adequately powered samples, using stringent definitions of treatment 
response (Robinson et al., in press).  
To date, no studies have examined the dose-response effect for CBT interventions using 
a sufficiently large sample and appropriate methods to examine patterns in diagnostically 
homogeneous groups. The present study aimed to address this gap in the literature through the 
analysis of a large multi-service dataset of low and high intensity CBT delivered in stepped 
care psychological services. The main objective was to determine an adequate dose of CBT for 
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2.1. Setting and interventions 
This study was conducted using multi-service archival data from 8 National Health Service 
(NHS) trusts in England, collected between 2014 and 2017. Together, these NHS trusts 
managed 16 Improving Access to Psychological Therapies (IAPT) services, covering socio-
economically diverse regions of England; including London, Cambridge, Cheshire & Wirral, 
Bury, Heywood, Middleton, Rochdale, Oldham, Stockport, Tameside & Glossop, Trafford, 
Barnsley and East Riding. Verbal consent was obtained and recorded in patients’ clinical 
records to collect weekly symptom measures to enable routine outcome monitoring. The 
assembly and analysis of a fully anonymised dataset was approved by the London - City & 
East NHS Research Ethics Committee (06/01/2016, Ref: 15/LO/2200). 
IAPT services deliver time-limited evidence-based psychological interventions for 
depression and anxiety organised in a stepped care model (Clark, 2018; NICE, 2011). Most 
patients initially access low intensity CBT (LiCBT), which is a brief (usually up to 8 sessions) 
guided self-help intervention based on principles of CBT. In the present sample, 90% of LiCBT 
interventions involved individual support, ~8% were delivered in groups, and ~2% delivered 
by blended care (online CBT plus telephone support). LiCBT is highly structured and follows 
treatment protocols based on a national training curriculum for psychological wellbeing 
practitioners (PWPs) (National IAPT Team, 2015) who practice under weekly supervision led 
by senior practitioners.  
Patients who do not respond to LiCBT are “stepped-up” to high intensity 
psychotherapies. For patients with major depressive disorder, available high intensity 
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treatments include CBT, interpersonal psychotherapy, short-term dynamic psychotherapy and 
person-centred counselling. Patients with post-traumatic stress disorder can access CBT or eye-
movement desensitization and reprocessing (EMDR). For other common mental disorders, 
high intensity CBT (HiCBT) is the most commonly recommended first line treatment. HiCBT 
involves structured, protocol-driven, disorder-specific interventions listed in the Roth & Pilling 
(2008) competency framework (usually up to 20 sessions). HiCBT was delivered by 
postgraduate-level psychotherapists whose training was based on a national curriculum 
(Department of Health, 2011). HiCBT therapists practice under regular clinical supervision 
(equivalent of 1 hour per week).  
Treatment duration in IAPT services can be highly variable, as it is collaboratively 
agreed with patients and supervisors, it is sometimes curtailed by dropout, and it can therefore 
differ from the number of sessions recommended in clinical guidelines. In the participating 
services, 27.6% of patients who started treatment only attended up to 3 sessions. Furthermore, 
5% of patients attended more treatment sessions than is specified by clinical guidelines (NICE, 
2011), and some (1%) accessed more than twice the number of recommended sessions. In this 
sample, 59.5% of patients only accessed low intensity interventions and 40.5% accessed high 
intensity interventions (of whom 17.1% were stepped up after LiCBT, and 23.5% were directly 
allocated to high intensity). Treatment recovery rates (as defined by Clark 2018) across these 
services ranged between 40.0% and 52.5%, which were broadly consistent with national 
performance indices reported by the IAPT programme1during the above period (44.8% to 
49.3%)*. 
2.2. Measures  
IAPT services collect outcome measures on a session-by-session basis to monitor treatment 
progress. The PHQ-9 is a measure of depression symptoms, where each of 9 questions is rated 
                                                 
* National IAPT performance reports are publicly available at: https://digital.nhs.uk/ 
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from 0 to 3, yielding an overall severity score between 0 and 27 (Kroenke, Spitzer, & Williams, 
2001). A cut-off of ≥10 has been recommended as providing the best trade-off between 
sensitivity (88%) and specificity (88%) for a diagnosis of major depression (Kroenke et al., 
2001), and a difference of ≥6 points between measurements is indicative of statistically reliable 
change (Richards & Borglin, 2011). The GAD-7 is a 7-item questionnaire used to identify 
anxiety disorders; each item is also rated between 0 and 3, with a total severity score between 
0 and 21 (Kroenke, Spitzer, Williams, Monahan, & Löwe, 2007). A cut-off score ≥8 is 
recommended to identify clinically important anxiety symptoms, with adequate sensitivity 
(77%) and specificity (82%) (Kroenke et al., 2007). A change of ≥5 points has been 
recommended to assess reliable change (Richards & Borglin, 2011).  
Secondary data: De-identified clinical records captured demographics (age, gender, 
disability, employment status), and clinical information (primary diagnoses, functional 
impairment, number of treatment sessions received at each step of care). Functional impairment 
was assessed using the Work and Social Adjustment Scale (WSAS) (Mundt et al., 2002) which 
rates overall functioning across 5 domains including: work, home management, social life, 
private leisure activities, and family relationships. 
2.3. Case selection process and sample characteristics 
In total, 146078 patients accessed treatment across participating services, including 
those who completed and those who dropped out. The majority of these (N = 116814; 80%) 
accessed LiCBT and/or HiCBT, with the remainder accessing other psychotherapies. The study 
sample (N = 102026) only included cases that accessed LiCBT and/or HiCBT and started 
treatment with clinically significant depression or anxiety symptoms (i.e. baseline scores above 
the diagnostic cut-offs). The rationale for selecting only low and high intensity CBT cases was 
twofold: these were the most widely accessed treatments, and other treatments had restricted 
sample sizes that precluded the detailed survival analyses described below. The study sample 
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included N = 76962 LiCBT cases and N = 36641 HiCBT cases (N = 12116 had LiCBT + 
HiCBT; N = 24525 only accessed HiCBT). The characteristics of the sample are summarised 




2.4. Statistical analyses 
Outcome definition: Sessional data enabled the identification of the first session at which a 
patient met criteria for reliable and clinically significant improvement (RCSI) on each of the 
outcome measures. RCSI was recorded (coded = 1) separately for each outcome measure, when 
scores improved by a magnitude greater or equal to the reliable change index compared to the 
initial treatment session, and if the score reduced below the diagnostic cut-off (Jacobson & 
Truax, 1991). The first observed RCSI signal was the primary event of interest in the time-to-
event analyses (event = remission of symptoms). All cases were also classified into two groups 
according to their RCSI outcome status at their final treatment session: responders (final 
session RCSI = 1) and non-responders (final session RCSI = 0). In this way, cases that had a 
short-lived improvement that was not maintained by the end of treatment (referred to as 
backsliding) (Robinson et al., in press) could be identified. 
Dose-response: Survival analyses identified the number of sessions required for 50%, 
75% and 95% of responders to attain remission of symptoms (RCSI). Kaplan-Meier curves 
were plotted separately for responders and non-responders to identify the stage of treatment at 
which these groups were reliably differentiated, expecting that some “false positive” cases may 
show initial signs of improvement that was not maintained to the end of treatment. Separate 
LiCBT and HiCBT survival analyses were run for each outcome measure. Cases that were 
stepped up were included separately in each of the subsets of cases according to the step of 
9 
 
treatment (i.e. their data contributed to both sets of analyses). Cases that did not show RCSI at 
all were included in survival analysis, and they contributed outcomes data up to the point of 
their last attended session (at which point their data was censored). Curves were plotted up to 
the time point (i.e. session) where there were at least N = 100 (non-censored) cases, to avoid 
misinterpretation of estimates yielded from small samples. The adequate dose was defined as 
the interval between 50% and 95% percentiles, where the lower boundary represents the 
minimum recommended number of sessions, and the upper boundary marks the point after 
which the probability of response to treatment was negligible (<5% probability). In cases where 
a diagnosis was recorded in clinical records, the above procedure was run for each diagnostic 
subgroup estimating post-treatment response rates (RCSI), mean and median survival times 
(with 95% confidence intervals). 
Time-to-remission: Cox regressions identified variables that might influence the 
relationship between treatment duration and outcomes. Candidate predictors were 
determined a priori, informed by previous outcome-prediction studies in stepped care 
psychological services (Delgadillo et al., 2014; Delgadillo, Huey, Bennett, & McMillan, 2017; 
Delgadillo, Moreea, & Lutz, 2016). The regression models for HiCBT cases additionally 
included a variable that contrasted cases that did or did not access prior LiCBT in their 
treatment pathway, to assess if accessing consecutive stepped care interventions influenced the 
dose-response findings. Cox regressions were applied in a dataset where missing values in 
candidate predictor variables were imputed by aggregating 25 iterations using the Markov 
Chain Monte Carlo method (Schunk, 2008). Diagnostic categories were not imputed because 
of the high number of sparsely populated categories; therefore, this analysis was carried out 
using a subset (N = 73542) of the sample included in the primary survival analysis.  
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Treatment duration (number of high intensity treatment sessions) and outcomes (RCSI) 
for HiCBT were compared between cases that did and did not have prior LiCBT, using Mann-
Whitney U tests and Chi-square analysis. 
 
3. RESULTS 
3.1. Response (RCSI) rates 
Overall, between 25.3% (PHQ-9) and 26.8% (GAD-7) of LiCBT cases were classed as 
responders by the end of treatment. Approximately 4.6% had false-positive RCSI signals 
before the end of treatment. Response rates were highly variable across the diagnostic groups 
treated with LiCBT (see Table 2 and supplementary appendix for further details). In particular, 
the response rates for social anxiety disorder, OCD, somatoform disorder and PTSD indicated 
that patients with these diagnoses had a low probability of improvement (< 25%) when treated 
with LiCBT. The response rates for HiCBT were between 38.6% (PHQ-9) and 39.3% (GAD-
7), and were consistent across diagnostic groups. HiCBT cases had a higher proportion of non-
responders with false positive RCSI signals (9.5%). Patients with somatoform disorder and 
specific phobias had the highest response rates (~50%), and those with PTSD had the lowest 
response rates (~33%). No significant differences in HiCBT response rates were found when 
comparing those that had prior LiCBT and those that only accesed HiCBT, using depression 
(38.5% vs. 38.6%; x2[1] = 0.02, p = .89) or anxiety measures (39.0% vs. 39.5%; x2[1] = 0.80, 




3.2. Dose-response patterns in LiCBT and HiCBT  
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Figure 1 presents Kaplan-Meier survival plots, modelling the number of sessions required to 
identify 50%, 75% and 95% of treatment responders. Findings were consistent across both 
outcome measures (PHQ-9, GAD-7). For LiCBT, 50% of responders were identified by session 
4, 75% by session 5, and 95% by session 7. The cumulative hazard function indicated that cases 
attaining RCSI by the 7th session were 3 times more likely to be classified as treatment 
responders.  For HiCBT, 50% of responders were identified by session 5, 75% by session 8, 
and 95% by session 14. The cumulative hazard function indicated that cases attaining RCSI by 




3.3. Dose-response by diagnostic group 
Table 2 summarises the dose-response parameters (50% to 95% boundaries), mean and median 
survival time estimates in each diagnostic group. For LiCBT, the minimum dose to identify 
50% of treatment responders ranged between 3–4 sessions, and 95% of responders were 
identified by sessions 6–8. The overlapping confidence intervals for mean survival times across 
groups revealed a highly homogeneous dose-response effect. For HiCBT, the minimum dose 
to identify 50% of treatment responders ranged between 4–6 sessions, and 95% of responders 
were identified by sessions 12–16. Mean survival times across groups were also highly 
homogeneous. The mean survival time for PTSD cases to respond (i.e. 6–16 sessions) was 
longer than most other conditions, apart from OCD. Specific phobias and somatoform disorders 
had lower mean survival times compared to other conditions; between 4–13 sessions were 
required to observe a response in 50% and 95% of cases. 
3.4. Predictors of time-to-remission 
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Table 3 summarises the results of fully adjusted Cox regression analyses. Patients with higher 
initial impairment (PHQ-9, GAD-7, WSAS), those prescribed antidepressants, those who were 
unemployed, and those who reported a disability had a decreased probability of attaining RCSI 
with increasing treatment duration (Hazard Ratio [HR] ~0.65 to 0.98). Older patients were 
statistically more likely to respond to lengthier treatments, although the effect size was 
negligible (HR ~1.00). Patients from a minority ethnic group and those with long-term physical 
health conditions were less likely to attain remission of anxiety symptoms (GAD-7) in lengthier 
LiCBT; although the effect sizes were small (HR ~0.95). In comparison to depression, patients 
with social anxiety disorder, OCD and PTSD had a lower probability of response with lengthier 
interventions (see hazard ratios in Table 3).  Furthermore, patients who accessed prior LiCBT 
tended to access a slightly higher mean number of HiCBT treatment sessions (8.80, SD = 5.37) 
compared to those who only accessed HiCBT (8.06, SD = 5.62); U(31499) = 116848963.00, p 
< .001. Yet, cases that accessed the full stepped care pathway had a significantly lower 
probability of response with lengthier HiCBT interventions, compared to those who only 





4.1. Summary of findings 
This study investigated the dose-response effect in evidence-based LiCBT and HiCBT 
interventions for common mental health problems treated in stepped care psychological 
services. The main findings indicate that the majority (95%) of LiCBT patients who attain 
reliable and clinically significant improvement (RCSI) do so within 7 sessions, and most 
HiCBT patients who attain RCSI do so within 14 sessions. These findings are consistent with 
the wider dose-response literature. Previous LiCBT studies have suggested an adequate dose 
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of 4–6 sessions (Delgadillo et al., 2014; Delgadillo, Kellett, et al., 2016). Other studies in 
primary care services which included HiCBT (among other treatments) have found an upper 
boundary ranging between 11 and 14 sessions (Howard et al., 1986; Wolgast, Lambert, & 
Puschner, 2003). As expected, predictors of time-to-remission were highly consistent with the 
prognostic factors highlighted by previous studies in similar services (Delgadillo, Kellett, et 
al., 2016; Delgadillo et al., 2017; Delgadillo, Moreea, et al., 2016). LiCBT adequate dose 
parameters were homogeneous across diagnostic groups; however, patients with social anxiety 
disorder, OCD and PTSD had poor response rates (<25%). Response rates for these diagnoses 
were considerably better when treated with HiCBT; but OCD and PTSD required more sessions 
(adequate dose of 6–16 sessions).  
These adequate dose parameters for LiCBT and HiCBT suggest important differences 
in response patterns. This is likely to be explained by differences in case-mix, since patients 
accessing HiCBT tend to have more severe conditions. The evident structural differences 
between treatments (e.g. LiCBT psychoeducational approach vs. HiCBT psychotherapeutic 
approach; 35 vs. 50-60 minute sessions) may also explain the differential response rates 
observed between treatments. These findings highlight the importance of considering dose-
response parameters alongside overall response rates. Otherwise, LiCBT may appear to be a 
more efficient option for the treatment of those diagnoses which clearly require HiCBT. These 
findings emphasise the importance of adhering to clinical guidelines that recommend HiCBT 
for social anxiety disorder and PTSD (NICE, 2011). The present results also indicate that 
HiCBT is a more appropriate treatment choice for OCD. 
Patients who accessed the full stepped care pathway (LiCBT+HiCBT) tended to access 
lengthier interventions, but had similar response rates to those who were directly allocated to 
HiCBT. An interesting implication is that exposure to prior LiCBT does not apparently confer 
any advantages (e.g. preparation, socialisation, early gains) for these cases – since their HiCBT 
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is neither briefer nor more effective. Furthermore, LiCBT+HiCBT cases were statistically less 
likely to respond to treatment with additional sessions. This latter finding may be explained by 
the influence of non-responders that persist with treatment (i.e. they have not dropped out early, 
which is why they eventually access HiCBT), but who nevertheless have a low probability of 
improvement with the treatments available in this stepped care context. 
We note that the response rates described in this study (ranging between 25.3% and 
39.3%) are markedly different to recovery rates that are publicly reported for IAPT services in 
England – which average around 50% (Clark, 2018; National Collaborating Centre for Mental 
Health, 2018). These differences are due to three methodological features. First, compared to 
IAPT recovery rates which classify cases based on symptomatic reductions below the cut-offs 
for PHQ-9 and GAD-7 (National Collaborating Centre for Mental Health, 2018), the strict 
RCSI criteria applied in this study additionally requires the observation of statistically reliable 
improvement and therefore yields more conservative estimates of treatment response. As 
shown in a methodological review on this topic (Robinson et al., in press),  studies that use 
RCSI criteria (rather than more lenient indices of improvement) tend to yield lengthier dose-
response parameters which are less likely to classify cases that take longer to benefit from 
therapy as non-responders. Second, we report RCSI rates separately for low and high intensity 
interventions, whereas IAPT recovery rates reflect improvements observed during the whole 
stepped care treatment pathway starting with an initial (pre-treatment) assessment. Third, the 
response rates in this study are not confounded by pre-treatment changes that occur between 
the initial assessment and the first therapy session, since survival analyses take the first 
treatment session as a baseline measure for the RCSI calculation. Previous studies have shown 
that pre-treatment improvements (which cannot be attributed to therapy) significantly influence 
patients’ probability of symptom remission (Delgadillo et al., 2014) and must therefore be 
controlled in dose-response analyses. Finally, the RCSI rates observed for HiCBT are 
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consistent with the effects observed in meta-analyses of controlled trials, which typically report 
a number needed to treat (NNT) of 2.6 (~38.5% response rate) (Cuijpers et al., 2013).  However, 
the RCSI rates for LiCBT were considerably lower, possibly owing to the inclusion of cases 
with conditions like social anxiety and PTSD, which evidently do not respond well to brief 
guided self-help, and should not be assigned to LiCBT according to clinical guidelines 
(National Collaborating Centre for Mental Health, 2018; NICE, 2011). Overall, the results 
presented in this study use a rigorous and conservative methodology, which follows best-
practice recommendations for dose-response research (Robinson et al., in press). 
4.2. Limitations 
A number of limitations are relevant to the interpretation of findings. As a naturalistic study, 
patients were not randomly allocated to treatments and therefore outcomes cannot be compared 
as if their characteristics were equally balanced across LiCBT and HiCBT. For this reason, the 
steps were analysed separately, in order to reflect the dose-response patterns observed in these 
naturally clustering samples of patients with milder and more severe problems. Diagnostic 
groupings were based on semi-structured assessments which may have produced inaccurate 
categorisation, so the comparisons across diagnostic groups should be interpreted with caution. 
PHQ-9 and GAD-7 measures were used to examine change across all diagnostic categories; 
whereas the availability of disorder-specific measures (i.e. specific measures for PTSD, OCD, 
etc.) may have provided more accurate indices of improvement. 
An important consideration is that, in the absence of a control group, it cannot be 
assumed that the remission of symptoms was necessarily due to the action of therapy.  It is 
plausible that some patients may have experienced spontaneous remission of symptoms. 
Nevertheless, this does not negate the relevance of the adequate dose concept, since it still 
offers a general guide as to when clinicians may expect to observe most cases with remission 
of symptoms (due to the effects of treatment or natural recovery). Finally, some cases treated 
16 
 
with LiCBT may have been discharged shortly after the first observation of symptom 
remission. It is possible that some of these cases may have been incorrectly identified as 
responders, since post-treatment follow-up data were not available to determine the stability of 
patients’ remission over time.  
4.3. Implications for clinical practice and policy 
Since the 1980’s, it has been recognised that some CBT patients attain rapid 
improvements during the initial therapy sessions (Rush, Kovacs, Beck, Weissenburger, & 
Hollon, 1981), which suggests that those who respond to therapy can be either rapid or gradual 
responders (Robinson et al., in press). The first group show signs of improvement within the 
first 4 sessions, which is recommended as the minimum number of sessions that should be 
offered in routine care. However, gradual responders require more sessions to benefit and tend 
to require HiCBT. Identifying the characteristics of these gradual responders (e.g. more 
complex cases) could inform the development of stratified models of care, in which such cases 
are immediately assigned to more intensive/longer treatments (Delgadillo et al., 2017; 
Delgadillo, Moreea, et al., 2016). The case for stratified care is further supported by the present 
results, since the probability of improvement was comparable between cases that were directly 
allocated to HiCBT (stratified care) and cases that accessed the full stepped care pathway 
(which is lengthier and costly). A more consistent and targeted application of stratified care for 
gradual responders could potentially improve the cost-effectiveness of treatment in this 
context. 
 Identifying adequate dose parameters offers a useful guide for therapists to support 
routine outcome monitoring. The 50% percentile (4th session of LiCBT; 5th session of HiCBT) 
is a key marker to plan a treatment review, assessing the case formulation, expectations, 
agreement on goals and tasks; particularly for non-improving patients to promote collaboration 
and adherence. The 75th percentile (5th session of LiCBT; 8th session of HiCBT) is a key time-
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point to identify obstacles to improvement, since patients who have not attained remission of 
symptoms by this point have a low probability (<25%) of benefitting from treatment. This 
should prompt consultation with a clinical supervisor in order to identify and formulate possible 
obstacles to improvement and to adjust the treatment plan. If no improvement is observed by 
the 95th percentile (7th session of LiCBT; 14th session of HiCBT), this marks an appropriate 
time to consider alternative treatment options. From an ethical and health economic point of 
view, continuing a treatment from which no benefit is being gained could be seen as a form of 
neglect, an inadequate use of limited healthcare resources, or at least as an opportunity cost, 
since the patient could have instead accessed other treatment options much sooner.  
Conversely, extending therapy beyond these dose-response intervals (up to 24 sessions) 
(Robinson et al., in press) is warranted for patients who have shown signs of RCSI, and we 
strongly caution against the arbitrary restriction of treatment sessions for these cases. Prior 
research has shown that IAPT services that offer a low mean number of treatment sessions tend 
to attain poorer clinical outcomes (Clark et al., 2018),  and therefore offering an adequate dose 
of therapy is central to effective and ethical practice (National Collaborating Centre for Mental 
Health, 2018). Although observing remission of symptoms is an important milestone in 
therapy, it is certainly not the optimal endpoint of treatment, since it is important to ensure that 
symptoms stabilise in the subclinical range before completing treatment. Our findings clearly 
show that some non-responders show “false positive” signals of improvement, and therefore 
observing stable RCSI across more than one measurement point is essential. Furthermore, the 
initial observation of remission usually marks the beginning of relapse prevention planning and 
subsequent booster sessions in order to maximize the chances of longer-term sustainability of 
improvements, as recommended in practice guidelines (National Collaborating Centre for 
Mental Health, 2018). Overall, these dose-response patterns yield practical recommendations 
18 
 
to guide the timely planning of treatment reviews, and evidence-based decisions to extend the 
duration of treatment or to consider alternative sources of support. 
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Table 1. Sample characteristics 
 
 
 All cases 
N = 102026 
LiCBT cases 
N = 76962 
HiCBT cases 
N = 36641 
Demographics    
     Male 35026/101613 (34.5%) 26422/76667(34.5%) 12407/36510 (34.0%) 
     Female 66587/101613 (65.5%) 50245/76667 (65.5%) 24103/36510 (66.0%) 
     Age (SD) 39.08 (14.58) 39.58 (14.82) 37.60 (13.65) 
     Unemployed 26195/95515 (27.4%) 18585/71675 (25.9%) 10983/35020 (31.4%) 
     Ethnicity    
 White British 80788/95739 (84.4%) 60726/ 72365 (83.9%) 29213/34360 (85.0%) 
 Other 14951/95739 (15.6%) 11639 /72365 (16.1%) 5147/34360 (15.0%) 
Clinical Characteristics    
     Diagnosis    
 Affective disorder 34144/90377 (37.8%) 26721 /67992 (39.3%) 11659/33154 (35.2%) 
 GAD  13902/90377 (15.4%) 10837/ 67992 (15.9%) 4828/33154 (14.6%) 
 Mixed anx and dep 26572/90377 (29.4%) 21231/ 67992 (31.2%) 7946/33154 (24.0%) 
 Panic / agoraphobia 3168/90377 (3.5%) 2283/ 67992 (3.4%) 1291/33154 (3.9%) 
 Social phobia 1877/90377 (2.1%) 953/ 67992 (1.4%) 1259/33154 (3.8%) 
 Specific phobia 714/90377 (0.8%) 355/ 67992 (0.5%) 451/33154 (1.4%) 
 OCD 2240/90377 (2.5%) 814/ 67992 (1.2%) 1840/33154 (5.5%) 
 PTSD 3039/90377 (3.4%) 957/ 67992 (1.4%) 2576/33154 (7.8%) 
 Somatoform disorder 722/90377 (0.8%) 349/ 67992 (0.5%) 508/33154 (1.5%) 
 Other 3884/90377 (4.4%) 3492/ 67992 (5.1%) 796/33154 (2.4%) 
     Baseline PHQ-9 score (SD) 16.21 (5.76) 15.53 (5.6) 16.22 (5.71) 
     Baseline GAD-7 score (SD) 14.61 (4.54) 14.14 (4.41) 14.93 (4.32) 
     Baseline WSAS score (SD) 21.31 (9.47) 20.51 (9.33) 21.86 (9.17) 
Mean number of sessions 
(SD, IQR) 
7.17 (5.18, 3 – 9) 3.70 (2.76, 1 – 6)  8.33 (5.51, 4 – 12) 
Notes: percentages exclude cases with missing data; GAD = generalized anxiety disorder; OCD = obsessive-compulsive disorder; PTSD 
= post-traumatic stress disorder; PHQ-9 = depression measure; GAD-7 = anxiety measure; WSAS = work and social adjustment 






Table 2. Kaplan-Meier survival estimates, stratified by diagnostic category, across intensities of CBT 
 
  Low intensity CBT 







time (95% CI) 
Median survival 
time (95% CI) 
Affective Disorder 24435 25.2 (24.7, 25.7) 4 – 7 4.09 (4.04, 4.14) 4.00 (3.94, 4.06) 
GAD 10465 32.6 (31.7, 33.5) 3 – 7 3.80 (3.74, 3.86) 3.00 (2.92, 3.08) 
Mixed 20162 26.9 (26.3, 27.5) 4 – 8 4.14 (4.08, 4.19) 4.00 (3.94, 4.06) 
Panic/ Agoraphobia 2212 33.1 (31.2, 35.1) 3 – 7 3.77 (3.63, 3.91) 3.00 (2.83, 3.17) 
Social Anxiety Disorder 910 19.3 (16.9, 22.0) 4 – 8 4.36 (4.07, 4.65) 4.00 (3.65, 4.35)  
Specific Phobia 350 31.1 (26.5, 36.2) 3 – 7 3.44 (3.14, 3.74) 3.00 (2.66, 3.34) 
OCD 803 13.2 (11.0, 15.7) 3 – 8 4.04 (3.63, 4.44) 3.00 (2.44, 3.56) 
PTSD 935 4.8 (3.6, 6.4) 4 – 7 4.13 (3.65, 4.62) 4.00 (3.20, 4.81) 
Somatoform disorder 343 22.2 (18.1, 26.8) 4 – 7 3.88 (3.45, 4.31) 4.00 (3.47, 4.54)  
Other 3318 30.1 (28.6, 31.7) 3 – 8 3.92 (3.79, 4.06) 3.00 (2.86, 3.14) 
 High intensity CBT 







time (95% CI) 
Median survival 
time (95% CI) 
Affective Disorder 10851 37.8 (36.9, 38.7) 5 – 14 6.30 (6.18, 6.41) 5.00 (4.86, 5.15)  
GAD 4706 48.1 (46.7, 49.5) 6 – 14 6.40 (6.24,6.56)  6.00 (5.81, 6.19) 
Mixed 7639 37.9 (36.8, 39.0) 5 – 14 6.46 (6.32, 6.61) 5.00 (4.82, 5.18) 
Panic/ Agoraphobia 1266 40.8 (38.1, 43.5) 5 – 14 6.35 (6.00, 6.69) 5.00 (4.57, 5.43) 
Social Anxiety Disorder 1198 42.8 (40.0, 45.6) 6 – 13 6.44 (6.12, 6.75) 6.00 (5.62, 6.38) 
Specific Phobia 434 47.5 (42.8, 52.2) 5 – 12 5.35 (4.88, 5.83) 5.00 (4.29, 5.71) 
OCD 1796 42.8 (40.5, 45.1) 6 – 16 6.82 (6.50, 7.14) 6.00 (5.65, 6.36) 
PTSD 2493 32.0 (30.2, 33.8) 6 – 16 7.20 (6.89, 7.51) 6.00 (5.61, 6.39) 
Somatoform disorder 498 55.0 (50.6, 59.3) 4 – 12 5.37 (4.98, 5.77) 4.00 (3.49, 4.51) 
Other 762 45.4 (41.9, 49.0) 5 – 16 6.10 (5.65, 6.55) 5.00 (4.61, 5.39)  
Notes: Responders = % of cases that attained reliable and clinically significant improvement (RCSI) by the end of treatment; 50 – 95% 
boundaries = the adequate dose of treatment; CI = confidence intervals; GAD= Generalised Anxiety Disorder; Mixed= Mixed anxiety and 
depression; OCD= Obsessive-Compulsive Disorder; PTSD = Post-Traumatic Stress Disorder; statistics for cases with affective disorders are 
based on the PHQ-9 depression measure; statistics for cases with anxiety and other disorders are based on the GAD-7 anxiety measure; details 
of all analyses using both outcome measures in each diagnostic subgroup are available in a supplementary appendix. 
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 Low intensity CBT  High intensity CBT 
 PHQ-9 (N = 40790)  GAD-7 (N = 44746)  PHQ-9 (N = 26467)  GAD-7 (N = 28796) 
Variables B (SE) Hazard Ratio 
(95% CI) 
 B (SE) Hazard Ratio 
(95% CI) 
 B (SE) Hazard Ratio 
(95% CI) 
 B (SE) Hazard Ratio 
(95% CI) 
PHQ-9 -0.02(0.002)*** 0.98(0.90,0.98)  -0.04(0.002)*** 0.96(0.96,0.96)  -0.03(0.002)*** 0.97(0.97,0.98)  -0.04(0.002)*** 0.96(0.96,0.97) 
GAD-7 -0.02(0.002)*** 0.98(0.98,0.99)  -0.02(0.002)*** 0.99(0.98,0.99)  -0.01(0.002)*** 0.99(0.98,0.99)  -0.02(0.002)*** 0.98(0.98,0.99) 
WSAS -0.02(0.001)*** 0.98(0.98,0.98)  -0.02(0.001)*** 0.98(0.98,0.99)  -0.02(0.001)*** 0.98(0.98,0.98)  -0.02(0.001)*** 0.98(0.98,0.99) 
Age 0.004(0.001)*** 1.00(1.00,1.01)  0.01(0.001)*** 1.01(1.004,1.005)  0.002(0.001)* 1.002(1.001,1.003)  0.003(0.001)*** 1.003(1.002,1.004) 
MEG -0.007(0.021) 0.99(0.95,1.03)  -0.04(0.02)* 0.96(0.92,1.00)  -0.03(0.02) 0.97(0.93,1.02)  -0.02(0.02) 0.98(0.94,1.03) 
Unemployed -0.43(0.021)*** 0.65(0.62,0.68)  -0.37(0.02)*** 0.69(0.66,0.72)  -0.34(0.02)*** 0.71(0.68,0.74)  -0.33(0.02)*** 0.72(0.69,0.75) 
Medication -0.07(0.015)*** 0.93(0.91,0.96)  -0.004(0.01) 0.99(0.97,1.02)  -0.05(0.02)** 0.95(0.92,0.98)  -0.04(0.02)* 0.96(0.93,0.99) 
LTC -0.03(0.018) 0.97(0.94,1.01)  -0.05(0.02)** 0.95(0.92,0.98)  -0.04(0.02) 0.96(0.93,1.00)  -0.04(0.02) 0.97(0.93,1.00) 
Disability -0.23(0.026)*** 0.79(0.75,0.83)  -0.17(0.03)*** 0.85(0.81,0.89)  -0.15(0.03)*** 0.86(0.81,0.91)  -0.10(0.03)*** 0.91(0.86,0.96) 
Diagnosis †            
 (GAD) 0.08(0.023)*** 1.09(1.04,1.14)  -0.04(0.02) 0.97(0.93,1.01)  0.06(0.03)* 1.07(1.01,1.12)  -0.06(0.03)* 0.95(0.90,0.99) 
 (mixed) -0.02(0.018) 0.98(0.94,1.01)  -0.06(0.02)*** 0.94(0.91,0.97)  0.02(0.02) 1.02(0.98,1.07)  0.01(0.02) 1.01(0.96,1.05) 
 (panic) 0.06(0.043) 1.07(0.98,1.16)  -0.02(0.04) 0.98(0.91,1.05)  -0.04(0.05) 0.96(0.87,1.05)  -0.03(0.04) 0.97(0.89,1.05) 
 (SocAnx) -0.20(0.077)* 0.82(0.71,0.96)  -0.31(0.07)*** 0.74(0.64,0.85)  0.01(0.05) 1.01(0.92,1.10)  -0.11(0.04)* 0.90(0.83,0.98) 
 (Phob) 0.28(0.116)* 1.33(1.06,1.67)  -0.07(0.09) 0.94(0.78,1.12)  0.13(0.08) 1.14(0.98,1.32)  -0.03(0.06) 0.98(0.86,1.10) 
 (OCD) -0.15(0.109) 0.86(0.70,1.07)  -0.43(0.09)*** 0.65(0.55,0.77)  -0.05(0.04) 0.95(0.88,1.03)  -0.27(0.04)*** 0.76(0.71,0.82) 
 (PTSD) -0.62(0.139)*** 0.54(0.41,0.71)  -0.68(0.14)*** 0.51(0.39,0.66)  -0.17(0.04)*** 0.84(0.79,0.90)  -0.26(0.04)*** 0.77(0.72,0.83) 
 (soma) 0.15(0.125) 1.16(0.91,1.48)  -0.03(0.10) 0.98(0.80,1.19)  0.20(0.07)** 1.22(1.06,1.40)  -0.002(0.06) 0.99(0.88,1.12) 
 (other) 0.01(0.036) 1.01(0.94,1.09)  -0.02(0.03) 0.98(0.92,1.05)  0.07(0.06) 1.07(0.96,1.19)  -0.01(0.05) 0.99(0.90,1.10) 
Prior LiCBT - -  - -  -0.15(0.02)*** 0.86(0.83,0.90)  -0.13(0.02)*** 0.88(0.85,0.91) 
B = regression coefficient; SE = standard error; CI = confidence intervals, PHQ-9= depression measure at initial therapy session; GAD-7= anxiety measure at initial therapy session; WSAS = measure of functional impairment at 
initial therapy session; MEG = minority ethnic group (reference category = white British); Medication = prescribed antidepressants; LTC = long-term health condition; † = reference category for diagnosis = affective disorders; 
GAD= Generalised Anxiety Disorder; mixed= Mixed anxiety and depression; panic = panic disorder / agoraphobia; SocAnx = social anxiety disorder; Phob = specific phobia; OCD= Obsessive Compulsive Disorder; PTSD = 







Figure 1. Kaplan-Meier survival curves comparing treatment responders to non-responders 
 
